Stay updated on Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page.

Latest updates to the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.4.2 added to the Record History; removed a government funding lapse notice and Revision: v3.4.1.SummaryDifference0.9%

- Check13 days agoChange DetectedAdded a government funding notice about the NIH Clinical Center's operating status. Updated the site revision to v3.4.1, replacing the previous v3.4.0 revision.SummaryDifference0.9%

- Check20 days agoChange DetectedUI changes include a glossary toggle and color-coded indicators for additions and deletions in the study history, with the revision label updated to v3.4.0. The previously listed No FEAR Act data note and the older revision label (v3.3.4) are superseded by the new formatting.SummaryDifference1%

- Check56 days agoChange DetectedRevision: v3.3.3 was added and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 were removed.SummaryDifference0.2%

- Check78 days agoChange DetectedA new revision (v3.3.2) has been added to the record history, and the previous revision (v3.3.1) has been removed.SummaryDifference0.1%

- Check85 days agoChange DetectedRevision history now lists a new version entry v3.3.1 and removes v3.2.0, representing a minor administrative update to the record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Myeloma: First Line & Re-treatment Clinical Trial page.